Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Tumor marker CYFRA-21-1 may be used as an additional parameter in the diagnosis, prognosis and follow-up of patients with non-small cell lung carcinoma (NSCLC), especially those with squamous cell carcinoma. From 1994 till 2001, the concentration of CYFRA-21-1 was determined in serum and/or pleural effusions of 166 patients with NSCLC, and in serum of 28 control subjects. Serum CYFRA-21-1median in the control, benign and malignant group was 0.8 ng/mL, 2.6 ng/mL and 6.3 ng/mL, respectively (p>0.05). In pleural effusions, CYFRA-21-1 median differed significantly between the benign (8.2 ng/mL) and malignant (146 ng/mL) group (p0,05). Nasuprot tome, u pleuralnom izljevu medijani CYFRA-21-1 benigne i maligne skupine od 8,2 ng/mL i 146 ng/mL bili su značajno različiti (p<0,0000). Osjetljivost i specifičnost CYFRA-21-1 u serumu bila je 62% odnosno 76%, a u pleuralnom izljevu su oba parametra iznosila 73%. Naši dosadašnji rezultati potvrđuju da je CYFRA-21-1 koristan dodatni parametar u razlikovanju benignih od malignih pleuralnih izljeva, ali ne i benignih od malignih seruma
